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Abstract 
Background: Fragile Histidine Triad protein (FHIT), as a known tumor sup-
pressor protein, has been proposed to play crucial role in inhibiting p53 deg-
radation by MDM2. Studies have confirmed FHIT interaction with p53 or 
MDM2, although functional interacting domains of FHIT with MDM2 and/or 
p53 are not completely defined. Thus, through determining the significant 
structural interacting domains of FHIT, information with regard to MDM2 and 
p53 would be provided. As there were no previous studies evaluating the in-
teraction of optimized important parts of target molecules, docking study was 
employed. 
Methods: Truncated structures of FHIT were screened to reveal critical sections 
engaging in FHIT interaction. HEX program was used in order to study the in-
teraction of target structures.  
Results: Given the total energy, FHIT structures (β5-7, α1) and (α1) of FHIT 
were showed to be better candidates in comparison with other structures in 
interaction with optimized MDM2 part. Furthermore, FHIT structures (β4-7, 
α1) and (β5-7, α1) were considered to be better than other structures in inter-
action with optimized p53 part. FHIT truncates which interact with MDM2 
optimized part exhibited lower energy levels than FHIT truncates which inter-
act with p53 optimized part.  
Conclusion: Our results can be useful for designing new inhibitors of this protein 
complex interaction which would result in tumor repression. 
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Introduction 
 
FHIT belongs to Histidine Triad (HIT) nu-
cleotide-binding protein superfamily and is 
considered a tumor suppressor 1. Genomic 
alterations and aberrant expression of FHIT 
have been correlated with many types of hu-
man cancers, including those of the lung 2-4, 
breast 5,6, cervix 7, colon 8, pancreas 9, prostate 
10, stomach 11,12, head and neck 13. 
 
 
 
 
Studies have shown the interaction of FHIT 
with MDM2 and the block of the interaction 
of MDM2 with p53, result in increased stabil-
ity of p53 14. Structurally, FHIT forms a dimer 
in solution (PDB code: 1FIT) and general 
structure of its protomer can be described as a 
common α+β type 15. An ordinary hydropho-
bic core is formed within the background of 
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the dimer 16. 
As prior studies demonstrate, MDM2 pro-
tein interacts with p53 directly 17,18 and MDM2 
can interact with FHIT (by immunoprecipita-
tion) 14. Moreover, other studies confirm the 
interaction of p53 and FHIT 14,19. Thus, it is 
logical to consider that FHIT and p53 have 
binding sites on MDM2 and perhaps these 
proteins could influence each other in binding 
to MDM2. 
As functional interacting domains of FHIT 
with MDM2 and/or p53 are not completely 
defined, therefore, by exploring the recogni-
tion site of interaction of FHIT-MDM2 with 
regard to p53 binding, one can evaluate the 
interaction and/or competition amid these pro-
teins for therapeutical approaches. Further-
more, the research for functional domain of 
FHIT may reveal the protein domain respon-
sible for tumor suppression. In addition, these 
studies will shed lights on the molecular 
mechanism of FHIT-MDM2-p53 complex.  
In this study, we assessed FHIT constructs 
interaction with MDM2 and p53 optimized 
models in silico. Results can be useful for de-
signing new inhibitors of this protein complex 
interaction which would result in tumor re-
pression. 
Materials and Methods 
 
Tertiary structure determination of FHIT trun-
cates 
PDB file of FHIT consisted of residues 2-
106 and 127-147, was achieved from protein 
databank (PDB code: 1FIT). Based on previ-
ous studies, fourteen segmented structures 
were constructed by truncating pdb file using 
ViewerLite42 (2010).  
PDB file of MDM2 and p53 optimized trun-
cates, consisted of amino acids 23-119 of 
MDM2 and 18-26 of p53, were achieved from 
protein databank (PDB code: 1T4F) with us-
ing ViewrLite42.  
 
FHIT, MDM2 and p53 modeling  
The structure prediction process consisted 
of sequence alignment, model building, and 
structure refinement stages 20. 
The tertiary structure of full FHIT was es-
tablished by homology modeling using the 
pdb three dimensional structure of FHIT, 
available from the protein databank (1FIT) as 
template by Swiss homology modeling server, 
and Modeller 9v7 (2009) package (Table 1) 21. 
Homology modeling was used to achieve 
the complete models of MDM2 and p53. Swiss 
homology modeling server and I-TASSER ser- 
ver were used for modeling the gaps of 
Table 1. FHIT truncated structures  
 
 FHIT β strands and α helices from N-terminal to C-terminal
Structure no. Amino acids N-terminal C-terminal 
1 (2-147) full FHIT β1, β2, β3, β4, β5 α1 β6, β7 α2 
2 (2-12) β1, β2 -- -- 
3 (2-43) β1, β2, β3, β4 -- -- 
4 (2-50) β1, β2, β3, β4, β5 -- -- 
5 (17-102) β3, β4, β5 α1 β6, β7 
6 (21-104) β4, β5 α1 β6, β7 
7 (22-102) β4, β5 α1 β6, β7 
8 (22-106) β4, β5 α1 β6, β7 
9 (34-106) -- α1 β6, β7 
9b * (34-102) -- α1 β6, β7 
10 (51-106) -- α1 β6, β7 
10b * (51-102) -- α1 β6, β7 
11 (53-73) -- α1 -- 
12 (75-106) β5 -- β6, β7 
12b * (75-102) β5 -- β6, β7 
 
    * Note: C9b, C10b, C12b were created by truncating 4 amino acids from the end point of each constructs 
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MDM2 and p53. Connecting MDM2 and p53 
five segments was performed by means of 
Modeller 9v7 program. Ramachandran plot 
generated by spdb viewer was used to assess 
the best models of each molecule. Nominees 
were evaluated using PROCHECK. Energy 
minimization of the obtained structures was 
performed using Swiss-Pdb Viewer 4.01 (2010). 
 
Computational interaction studies 
Docked conformations and interaction en-
ergies were achieved using the protein-protein 
docking package HEX 5.1 (2008). During 
docking operation by HEX, the free energies 
were estimated based on shape complementa-
rity only and shape/electrostatics. The mean 
computational time used for a complex was 
about 30 min for HEX. HEX was executed on 
an IBM attuned computer running at 4 GB 
RAM and 2.5 GHz Dual Core™2 Intel® CPU. 
 
Results 
 
 Determination and generation of FHIT truncat-
ed structures 
As mentioned before, we created 14 differ-
ent truncated structures (Table 1), namely 2 to 
12b and compared them with full length FHIT 
(Structure 1, Table 1) to recognize the most 
critical regions of FHIT involved in the inter-
action with MDM2 and p53 and also evaluate 
trimeric interaction complex. Tertiary struc-
tures of MDM2 and p53 optimized truncates, 
composed of amino acids 23-119 and 18-26, 
were obtained from protein databank (PDB 
code: 1T4F) (Figure 1). 
 
Complete FHIT, MDM2 and p53 models 
FHIT (Structure 1, Table 1), MDM2 and 
p53 structures were generated by homology 
modeling (Figure 2). 
 
Interaction analysis 
HEX results: The docking results performed 
by HEX for FHIT truncates with complete 
MDM2 and MDM2 optimized part, p53 opti-
mized part are shown in tables 2-4. 
Figure 1. MDM2 optimized part (left), p53 optimized part 
(between) and 1T4F (PDB file) (right) 
Figure 2. MDM2 complete model (left), p53 complete model 
(between) and FHIT complete model (right) 
Table 2. Docking interaction energies (kJ/mol) of FHIT truncates with MDM2 and p53 optimized part 
 
Target: FHIT constructs β strands α helices E-total (MDM2 optimized part) E-total (p53 optimized part)
1 (Full length) β1-7 α1-2 -426.58 -325.53 
2 (2-12) β1-2 -- -357.46 -227.31 
3 (2-43) β1-4 -- -425.62 -309.70 
4 (2-50) β1-5 -- -459.68 -324.75 
5 (17-102) β3-7 α1 -460.98 -358.14 
6 (21-104) β4-7 α1 -462.99 -374.86 
7 (22-102) β4-7 α1 -434.99 -321.44 
8 (22-106) β4-7 α1 -456.14 -345.26 
9 (34-106) β5-7 α1 -487.87 -365.59 
9b (34-102) β5-7 α1 -479.24 -331.74 
10 (51-106) β6-7 α1 -456.22 -347.92 
10b (51-102) β6-7 α1 -457.84 -344.99 
11 (53-73) -- α1 -477.68 -275.81 
12 (75-106) β6-7 -- -423.27 -279.01 
12b (75-102) β6-7 -- -386.03 -289.22 
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In table 2, E-totals refer to the interaction 
of FHIT constructs with partial MDM2 of 
1T4F (cut p53 optimized part) and p53 opti-
mized part of 1T4F (deleted MDM2 part). 
Table 5 indicates docking total energy of 
complete MDM2 and p53 as well as MDM2 
optimized part and p53 optimized part. 
Considering the shape and electrostatic en-
ergies, FHIT truncated forms 9 (β5-7, α1), 9b 
(β5-7, α1) and 11 (α1) interact with MDM2 
optimized part at lower total energy and the 
interaction of FHIT with p53 optimized part is 
better for structures 6 (β4-7, α1), 9 (β5-7, α1) 
and 5 (β3-7, α1) based on total energy (Ta 
 
ble 2). 
Table 5 demonstrates total interaction ener-
gy of optimized part of MDM2 with opti-
mized part of p53 obtained from PDB protein 
databank. Docking interaction energy of these 
two structures is -407.20 (kJ/mol). This table 
also shows total interaction energy of MDM2 
complete model and p53 complete model  
(-399.25 kJ/mol). 
As table 3 shows, truncated structures 7 
(β4-7, α1), 6 (β4-7, α1) and 4 (β1-5) interact 
with MDM2 complete model with lower E-
shape (shape energy). Truncated structures 4 
(β1-5), 5 (β3-7, α1) and 7 (β4-7, α1) dock 
Table 3. Docking interaction energies (kJ/mol) of FHIT truncates with MDM2 complete model 
 
Target: FHIT truncates β strands α helices E-total (MDM2 complete model) E-shape (MDM2 complete model) 
1 (Full length) β1-7 α 1-2 -459.53 -514.69 
2 (2-12) β1-2 -- -470.78 -404.28 
3 (2-43) β1-4 -- -481.25 -459.89 
4 (2-50) β1-5 -- -564.96 -537.94 
5 (17-102) β3-7 α1 -526.42 -523.61 
6 (21-104) β4-7 α1 -519.84 -560.65 
7 (22-102) β4-7 α1 -523.92 -579.12 
8 (22-106) β4-7 α1 -458.58 -508.41 
9 (34-106) β5-7 α1 -501.87 -499.37 
10 (51-106) β6-7 α1 -474.26 -471.92 
11 (53-73) -- α1 -476.76 -420.12 
12 (75-106) β6-7 -- -451.34 -461.33 
 
Table 4. Docking interaction energies (kJ/mol) of MDM2 optimized part with FHIT truncates, interaction of this complex with p53 optimized 
part, interaction of p53 optimized part with FHIT truncates, and interaction of this complex with MDM2 optimized part 
 
Target: FHIT truncates β strands α helices E-total (MDM2 optimized part) 
E-total (MDM2  
optimized part, p53  
optimized part) 
E-total (p53  
optimized part) 
E-total (p53  
optimized part, MDM2  
optimized part) 
1 (Full length) β1-7 α1-2 -426.58 -457.02 -325.53 -476.38
2 (2-12) β1-2 -- -343.90 -308.59 -227.31 -480.43
3 (2-43) β1-4 -- -425.62 -446.11 -309.70 -448.76
4 (2-50) β1-5 -- -459.68 -447.22 -324.75 -441.16
5 (17-102) β3-7 α1 -460.98 -443.05 -358.14 -482.89
6 (21-104) β4-7 α1 -462.99 -440.05 -374.86 -452.90
7 (22-102) β4-7 α1 -434.99 -419.11 -321.44 -472.99
8 (22-106) β4-7 α1 -456.14 -372.62 -345.26 -447.14
9 (34-106) β5-7 α1 -487.87 -352.35 -365.59 -472.57
9b (34-102) β5-7 α1 -479.24 -440.94 -331.74 -471.50
10 (51-106) β6-7 α1 -456.22 -417.22 -347.92 -453.76
10b (51-102) β6-7 α1 -457.84 -411.13 -344.99 -484.31
11 (53-73) -- α1 -477.68 -357.41 -275.81 -431.02
12 (75-106) β6-7 -- -423.27 -430.00 -279.01 -428.81
12b (75-102) β6-7 -- -386.03 -436.80 -289.22 -438.68
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with MDM2 complete model at lower total 
energy (shape and electrostatic energy) when 
compared to others. In general, structures in 
lower E-shape results have lower E-total (E-
shape plus E-force) results.  
Since there is a probability that FHIT and 
p53 might interact with MDM2 in a competi-
tive way, we have also examined the interac-
tion of triple protein complex FHIT, MDM2 
optimized model and p53 optimized part in 
two stages. For this analysis, after interaction 
of FHIT constructs with optimized part of 
MDM2, these complexes (FHIT truncates 
with MDM2 optimized part) were tested with 
optimized part of p53. Similarly, following 
the interaction of FHIT truncates with opti-
mized part of p53, the interaction of these 
complexes with optimized part of MDM2 was 
performed.  
As table 4 illustrates, the complexes of trun-
cates 2 (β1-2), 9 (β5-7, α1), 11 (α1) and 
MDM2 optimized part interact with p53 op-
timized part in higher total energy status. On 
the other hand, complexes of p53 optimized 
part with truncates 12 (β6-7), 11 (α1) and 12b 
(β6-7) interact with MDM2 optimized part in 
a higher total energy circumstance. Figure 3 
represents three dimensional view of some 
FHIT, MDM2 optimized part, and p53 opti-
mized part interaction view. Figure 4 repre-
sents two dimensional view of C9 (FHIT34-
Figure 4. FHIT truncates, MDM2 optimized part, and p53 optimized part interactions,   two dimensional view. A, B) C9 FHIT trun-
cate and p53 optimized part interaction complex challenged with MDM2 optimized part; A) five residues of C9 involve in hydrogen 
bond in interaction with MDM2 optimized part, in this complex; B) p53 optimized part binding pocket. This binding pocket is com-
posed of 17 residues in which three of them involve in hydrogen bond (Arg18, Asp21, and Trp23). C and D) C9 FHIT truncate and 
MDM2 optimized part interaction complex challenged with p53 optimized part; C) four residues of C9 involve in hydrogen bond in 
interaction with MDM2 optimized part, in this complex; D) p53 binding pocket. This binding pocket is composed of 14 residues in 
which one of them involve in hydrogen bond (Arg18) 
Table 5. Docking interaction energies (kJ/mol) of MDM2 model 
with p53 model and optimized part of MDM2 with optimized 
part of p53 
 
Receptor Ligand E-total
MDM2 (1-484) p53 (1-392) -399.25 
MDM2 (Glu23-Val119) p53 (Arg18-Leu26) -407.20 
 
MDM2 complete model (1-484) and optimized part (Glu23-Val119); 
p53 complete model (1-392) and optimized part (Arg18-Leu26) 
 
Figure 3. FHIT truncates, MDM2 optimized part, and p53 
optimized part interactions three dimensional view. A) Three 
dimensional representation of 1T4F (PDB file); B) C9 FHIT 
truncate, MDM2 optimized part interaction view; C and D) 
C9 FHIT truncate and MDM2 optimized part interaction 
complex challenged with p53 optimized part; E) C9 FHIT 
truncate and p53 optimized part interaction view; F) C9 
FHIT truncate and p53 optimized part interaction complex 
challenged with MDM2 optimized part 
Eslamparast A, et al 
Avicenna Journal of Medical Biotechnology, Vol. 6, No. 2, April-June 2014 69
106), MDM2 optimized part, and p53 opti-
mized part important interactions view. 
 
Discussion 
 
Three dimensional structures of proteins 
are essential for computational interaction re-
search. As only parts of FHIT, MDM2 and 
p53 had been determined as three dimensional 
structures in protein databank, we performed 
modeling for their structures. 
Docking is considered as an in silico meth-
od for investigating the best interaction be-
tween two molecules which can be used in the 
rational drug design 22. HEX program actually 
accelerates the process compared with the 
classical FFT docking algorithms 23. Earlier 
studies have proved that HEX method has no 
limitation for protein size 24. 
We tested docking of MDM2, p53 optimiz-
ed parts as the receptor to compare the inter-
action tendencies of a special motif or a group 
of them within FHIT. The results of our pre-
vious docking study indicate that interaction 
of full FHIT with p53 (E-total: -568.66) and 
MDM2 (E-total: -459.53) is associated with 
lower total energy compared to the interaction 
of the complete MDM2 with p53 (E-total:  
-399.25). The abovementioned interaction oc-
curred with higher total energy in comparison 
with the optimized p53 and MDM2 (E-total:  
-407.20). Moreover, subsequent to MDM2 
and p53 optimization, it appeared that their 
relative tendency was augmented compared to 
their corresponding complete models.  
Given the interaction of full FHIT with op-
timized models of p53 and MDM2, it is evi-
dent that FHIT truncates have higher affinity 
to interact with MDM2 optimized part than 
p53 optimized model. According to the inter-
action values, FHIT truncates interact with 
optimized MDM2 at lower E-total than opti-
mized part of p53 and the total energies of 
docking interactions are directly related to 
shape energies of the mentioned interactions. 
Our results revealed that the tendency of β4-7, 
α1 segment of FHIT to p53 optimized model 
is more than other parts. Likewise, the β5-7, 
α1 structure of FHIT has more affinity to 
MDM2 optimized part than other forms. 
Thus, one can suggest the β5-7, α1 segment of 
FHIT as an interacting domain for both p53 
and MDM2. 
 
Having studied the above mentioned inter-
actions, we found that FHIT remarkably has 
better affinity to bind MDM2 optimized part 
in the presence of p53 and MDM2 optimized 
models in most of the cases. Even though it 
can bind to p53 optimized model with low 
energy, when MDM2 optimized part is added 
to the model, the interaction with p53 opti-
mized part is further attenuated (Table 4). In-
terestingly, complex of FHIT truncates inter-
acting with MDM2 optimized part at lower 
total energy usually interacts with p53 opti-
mized model at higher total energy. Thus, the-
se findings indicate a sequence/conformation 
specificity of FHIT truncates for interacting 
with MDM2 or p53. 
 
E-totals of interaction between MDM2 op-
timized model (for interaction with p53) and 
FHIT truncates reveal that α1 is important in 
these interactions. E-totals of interaction be-
tween p53 optimized model (for interaction 
with MDM2) and FHIT truncates show that 
β5-7 and α1 are important parts in these inter-
actions. 
 
Experimental reports using yeast two-hy-
brid 25 and immunoprecipitation indicate that 
p53 at amino acids 1-41 25 or 1-52 26 interacts 
with MDM2. On MDM2, the interaction at 
amino acids 1-118 25 or 19-102 26 is the bind-
ing site to p53. Site-directed mutagenesis con-
firms the Leu14, Phe19, Leu22, and Trp23 of 
p53 are essential amino acids for interaction 
27. The co-crystal structure of MDM2-p53 
complex shows that Phe19, Trp23, and Leu26 
are three main interacting residues in p53 28. 
MDM2 directly binds to p53 18 and regu-
lates p53 function and degradation 29-33. More-
over, a number of studies reported p53 and 
FHIT interaction 14,19 and their possible asso-
ciation 34. As shown in table 3, in p53-MDM2 
interaction, the significant part of p53 is ami-
no acids 18-26, and the important part of 
MDM2 is amino acids 23-119 35. Based on 
our results, the interaction sites of FHIT with 
70 
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MDM2 and p53 have overlapping parts. The 
best interaction site for MDM2-FHIT is resi-
dues 34-106 containing β5-7, α1. Conversely, 
for FHIT-p53 interaction, amino acids 21-104 
containing β4-7, α1 are involved. However, 
residues 34-104 are involved in both interac-
tions (Table 2). Interestingly, when the inter-
action of FHIT with MDM2 optimized part is 
challenged with p53 optimized part, the inter-
action site is different from interaction with 
MDM2 optimized part alone.  
Based upon these results, the interaction 
sites of FHIT with MDM2 and p53 are differ-
ent with overlapping parts. FHIT binds to 
MDM2 with lower energy in the presence of 
p53 and the binding site shifts toward FHIT-
MDM2 interaction. These data provide infor-
mation involving competition of FHIT with 
p53 in binding to MDM2. Then, in the pres-
ence of FHIT, p53 is released from MDM2 
and can increase apoptosis or cell cycle arrest. 
Figures 3 and 4 confirm the results indicated 
in the tables. 
 
Conclusion 
 
In conclusion, our findings provide valua-
ble information to understand the molecular 
mechanism of FHIT-MDM2-p53 complex 
formation and the design of inhibitory com-
pounds. The truncated parts of FHIT with 
higher absolute E-total energy interacting with 
MDM2 optimized part [parts (β5-7, α1) and/ 
or (α1)] can be effective in inhibiting degrada-
tion of p53 through altering MDM2 interac-
tion with p53. Also, the truncated parts of 
FHIT with higher absolute E-total energy in-
teracting with p53 optimized part [parts (β5-7, 
α1) and (β4-7, α1)] can be effective in inhibit-
ing degradation of p53 through altering MDM2 
interaction site with p53.  
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